作者: Firas H. Kobeissy , Andrew K. Ottens , Zhiqun Zhang , Ming Cheng Liu , Nancy D. Denslow
DOI: 10.1074/MCP.M600157-MCP200
关键词: Traumatic brain injury 、 Proteomics 、 Protein purification 、 Neuroproteomics 、 Medicine 、 Pharmacology 、 Biomarker discovery 、 Hexokinase 、 Transferrin 、 Synaptotagmin 1
摘要: Approximately two million traumatic brain injury (TBI) incidents occur annually in the United States, yet there are no specific therapeutic treatments. The absence of diagnostic endpoints was identified as a significant roadblock to TBI development. To this end, our laboratory has studied mechanisms cellular for biomarker discovery and possible strategies. In study, pooled nao¨ve injured cortical samples (48 h postinjury; rat controlled impact model) were processed analyzed using differential neuroproteomics platform. Protein separation performed combined cation/anion exchange chromatography-PAGE. Differential proteins then trypsinized with reversed-phase LC-MSMS protein identification quantitative confirmation. results included 59 components which 21 decreased 38 increased abundance after TBI. Proteins collapsin response mediator 2 (CRMP-2), glyceraldehyde-3-phosphate dehydrogenase, microtubule-associated MAP2A/2B, hexokinase. Conversely C-reactive protein, transferrin, breakdown products CRMP-2, synaptotagmin, II-spectrin found be elevated changes above mentioned confirmed by immunoblotting. Results from work provide insight into yield putative biochemical markers potentially facilitate patient management monitoring severity, progression, treatment injury. Molecular & Cellular Proteomics 5:1887–1898, 2006.